SLC2A3 and breast cancer: Subsequent investigations revealed that GLUT3 not only contributes to the transport of gemcitabine in breast cancer cells but also mediates gemcitabine sensitivity in PC; the knockdown of GLUT3 diminished the chemotherapeutic efficacy of gemcitabine, while SIRT7 knockdown enhanced sensitivity, an effect that was abrogated upon GLUT3 knockdown.